Analysts at Leerink Partnrs decreased their FY2025 earnings estimates for shares of Opthea in a report issued on Monday, ...

Opthea's Phase 3 COAST trial for wet AMD did not meet its primary endpoint, raising financial concerns as the company faces ...

Biotechnology firm Opthea has warned investors its solvency is in question after the failure of a major clinical trial into ...

The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on ...

Opthea (NASDAQ:OPT – Get Free Report) was downgraded by research analysts at Leerink Partners from an “outperform” rating to ...

One of two of Opthea's phase III trials for a common eye disease has failed to meet its objectives, casting doubts on the ...

A coterie of Mayne Pharma holders reckons US bidder Cosette's $600 million tilt does not reflect the upside of the improving Mayne business.

The hedge fund run by veteran stockpicker Phil King has told investors that the eye treatment play is worth 20¢ per share. It ...

Australia-based Opthea, a biopharma developing therapies for progressive retinal diseases, has announced results from its ...

Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was ...